1. Ustekinumab-induced subacute cutaneous lupus
Emma Tierney, MPharm, BMBS, MRCPI, Shivashini Kirthi, MB, Bch, BAO, MRCPI, Bart Ramsay, MBBS, MD, FRCPI, Kashif Ahmad, MBBS, MRCPI, MD 
JAAD Case Reports 
Volume 5, Issue 3, Pages (March 2019)
DOI: /j.jdcr
Copyright © 2019 American Academy of Dermatology, Inc. Terms and Conditions

2. Fig 1 SCLE rash on patient's back after second dose of ustekinumab.
JAAD Case Reports 2019 5, DOI: ( /j.jdcr )
Copyright © 2019 American Academy of Dermatology, Inc. Terms and Conditions

3. Fig 2 SCLE rash on patient's chest after second dose of ustekinumab.
JAAD Case Reports 2019 5, DOI: ( /j.jdcr )
Copyright © 2019 American Academy of Dermatology, Inc. Terms and Conditions

4. Fig 3
Histology (H&E) of skin biopsy shows features of lupus erythematosus: mild hyperkeratosis, a normal granular layer, and focal interface change with necrotic keratinocytes. (Hematoxylin-eosin stain.)
JAAD Case Reports 2019 5, DOI: ( /j.jdcr )
Copyright © 2019 American Academy of Dermatology, Inc. Terms and Conditions

5. Fig 4
Resolution of subacute cutaneous lupus erythematosus rash 10 weeks after discontinuing ustekinumab.
JAAD Case Reports 2019 5, DOI: ( /j.jdcr )
Copyright © 2019 American Academy of Dermatology, Inc. Terms and Conditions